Myriad Genetics Receives Foreign Patents for BRCA Family Genes | GenomeWeb

NEW YORK, May 15 – Myriad Genetics has received eight foreign patents covering the BRCA1 and BRCA2 breast and ovarian cancer genes and their use in the development of therapeutic and predictive medicine products, the company announced on Tuesday.

The European patent is for “Method for Diagnosing a Predisposition for Breast and Ovarian Cancer” using the BRCA1 and 2 genes. Four Canadian patents, two Australian, and one New Zealand patent cover the BRCA genes. Nine patents had already been issued in the United States, according to the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.